PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
Clinical trial NCT05346107 · UNKNOWN
Trial details
- NCT number
- NCT05346107
- Sponsor
- Xijing Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-01
- Primary completion
- 2022-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.